Journal
ONCOTARGET
Volume 6, Issue 5, Pages 3195-3210Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3084
Keywords
androgen receptor; eIF4E; MNK; novel retinamides; prostate cancer
Categories
Funding
- NIH
- NCI [RO1CA129379]
- University of Maryland School of Medicine
- Center for Biomolecular Therapeutics (CBT), Baltimore, USA
- University of Maryland School of Medicine Toxicology Program
Ask authors/readers for more resources
Androgen receptor (AR) and MNK activated eIF4E signaling promotes the development and progression of prostate cancer (PCa). In this study, we report that our Novel Retinamides (NRs) target both AR signaling and eIF4E translation in androgen sensitive and castration resistant PCa cells via enhancing AR and MNK degradation through ubiquitin-proteasome pathway. Dual blockade of AR and MNK initiated eIF4E activation by NRs in turn induced cell cycle arrest, apoptosis, and inhibited cell proliferation. NRs also inhibited cell migration and invasion in metastatic cells. Importantly, the inhibitory effects of NRs on AR signaling, eIF4E translation initiation and subsequent oncogenic program were more potent than that observed with clinically relevant retinoids, established MNK inhibitors, and the FDA approved PCa drugs. Our findings provide the first preclinical evidence that simultaneous inhibition of AR and eIF4E activation is a novel and efficacious therapeutic approach for PCa, and that NRs hold significant promise for treatment of advanced prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available